(2023), New England Journal of Medicine 389(6), DOI 10.1056/NEJMoa2301972 Statistics from clinical literature Developer: Eli Lilly and Company , code name LY3437943 Mechanism: triple agonist acting at GLP-1 , GIP and glucagon receptors, the first such peptide in advanced clinical development Phase 2 obesity trial (NEJM 2023) results at 12 mg/week dose, n=338: 24.2 % mean reduction in body weight at 48 weeks 25.8 % loss of body fat (DEXA) 9.7 % reduction in hemoglobin A1c in prediabetic patients Phase 2 type 2 diabetes trial (Lancet 2023): 2.02 % point A1c reduction at 36 weeks vs
Mild nausea or brief changes in digestion are the most common initial signs that your system is adjusting to slower digestion
Participants lost an average of 16.6% of their body weight, a significant improvement compared to just 3.2% in the placebo group
FDAs investigator noted bluntly that Puroleas AI never told [them] about the process validation requirement ( [2] ), which shows the danger of outsourcing compliance awareness to an algorithm
There is no one-size-fits-all answer, and we do not default to the same protocol for every patient
